|
|
Post by #NoMoreNeedles on Jan 9, 2019 14:55:49 GMT -5
Sep 4, 2018: United Therapeutics
Jul 27, 2018: Tanner Pharma Group
May 9, 2018: Cipla
May 31, 2017: Biomm
May 4, 2017: OneDrop
Nov 9, 2016: Sanofi
Jun 10, 2016: JDRF
Jan 21, 2016: RLS
Nov 13, 2012: Colby Pharmaceuticals
Apr 30, 2012: Tolero Pharmaceuticals
Feb, 2012: Torrey Pines Institute
Jan 19, 2011: TechnoVax
Sep 26, 2008: Rose Pharma
May 8, 2008: The Leukemia & Lymphoma Society
|
|
|
|
Post by mannmade on Jan 9, 2019 15:00:33 GMT -5
Torrey Pines, Technovax?
|
|
|
|
Post by #NoMoreNeedles on Jan 9, 2019 15:17:49 GMT -5
Couldn't find any PR for Torrey Pines partnership
|
|
|
|
Post by brentie on Jan 9, 2019 15:23:18 GMT -5
Sep 4, 2018: United Therapeutics Jul 27, 2018: Tanner Pharma Group May 9, 2018: Cipla May 31, 2017: Biomm May 4, 2017: OneDrop Nov 9, 2016: Sanofi Jun 10, 2016: JDRF Jan 21, 2016: RLS Nov 13, 2012: Colby Apr 30, 2012: Tolero Here's a few more... Rose Pharmaceuticals www.mannkindcorp.com/Collateral/Documents/English-US/2009%20ROSE-010%20poster%20Final%2008.26.09.pdfTorrey Pines www.valuewalk.com/2015/06/mannkind-pain-management/Technovax technovax.com/TechnoVaxPresentation-Nov2012-IC-DC.pdfThe Leukemia & Lymphoma Society investors.mannkindcorp.com/news-releases/news-release-details/leukemia-lymphoma-society-and-mannkind-corporation-announce |
|
|
|
Post by brentie on Jan 9, 2019 15:27:13 GMT -5
Couldn't find any PR for Torrey Pines partnership This is the original announcement but it's no longer available online. PORT ST. LUCIE — Torrey Pines Institute for Molecular Studies could begin testing a new pain medication on humans as early as 2013, Torrey Pines founder Dr. Richard Houghten said Tuesday. The drug would be a breakthrough in pain medication at a time when state and local legislators are trying to curb addiction to prescription drugs. The drug is designed to provide quick pain relief while eliminating side effects such as addiction, respiratory depression and adverse psychological consequences. "In Port St. Lucie because of what the state, the city and the county and whatnot have done, we've been able to develop these methods so that we're now to the point where we have advanced compound that will be going into humans, going into man in 2013," Houghten told guests gathered at the Economic Development Council of St. Lucie monthly luncheon. Torrey Pines opened a $40 million, 100,000-square-foot facility in January 2009 and has hired about 107 of the 189 jobs promised by 2016. The nonprofit has plans to hire another 13 before June, Houghten said. Torrey Pines has more room to operate and do research now that Vaccine & Gene Therapy Institute of Florida has moved into its own building down the street in January. VGTI had occupied the third floor of Torrey Pines' building. While both nonprofits showed gratitude and collaborated with one another to make the situation work, both are happy to have their own space. After the lunch, Houghten expanded on the new drug's possibilities. "It's actually pretty marvelous," Houghten said. "You can't (overdose) on this drug." The drug is being developed in partnership with Mannkind Corp., which has created a small device that allows people to inhale medicine. By inhaling, the medicine can relieve pain quicker than through pill form, Houghten said. "Our pain compound, if it all works out, ... if you can take that pain compound and just inhale within just 30 seconds to a minute, your pain will be alleviated," Houghten said. "So you can see that that can be a real important step." The drug has been tested on two separate animal groups and Houghten said the drug will be tested on a third before going before the U.S. Food and Drug Administration, which must give approval for human trials. Houghten said the unique nature of the drug could make it easier to get approval. "You never really quite know," he said. "Right now, everything's looking really good. ... We can't get a high enough dose that causes a problem." Patients also do not build up a tolerance to the medicine, whereas other pain relievers require patients to take more and more to get the same effect. Houghten said he is thrilled with the drug's progress. "In reality is if it's 2014 (before human testing), I'm still going to be happy," Houghten said. "I don't think it's going to be a problem with the FDA. It's very simple what we want to do, so we can show them clearly here's the effective dose, here's the toxic dose. That's 90 percent of it right there. It's effective and it's not toxic." www.tcpalm.com/news/2012/feb/07/torrey-pines-could-begin-human-testing-of-new-in/ |
|
|
|
Post by peppy on Jan 9, 2019 15:33:00 GMT -5
quote; "The drug has been tested on two separate animal groups and Houghten said the drug will be tested on a third before going before the U.S. Food and Drug Administration, which must give approval for human trials."
Do we know? The drug did not work out?
"You never really quite know," he said. "Right now, everything's looking really good. ... We can't get a high enough dose that causes a problem."
|
|
|
|
Post by goyocafe on Jan 9, 2019 15:43:48 GMT -5
quote; "The drug has been tested on two separate animal groups and Houghten said the drug will be tested on a third before going before the U.S. Food and Drug Administration, which must give approval for human trials." Do we know? The drug did not work out? "You never really quite know," he said. "Right now, everything's looking really good. ... We can't get a high enough dose that causes a problem." The MNKD book of never ending chapters. |
|
|
|
Post by #NoMoreNeedles on Jan 9, 2019 15:45:40 GMT -5
Sep 4, 2018: United Therapeutics
Jul 27, 2018: Tanner Pharma Group
May 9, 2018: Cipla
May 31, 2017: Biomm
May 4, 2017: OneDrop
Nov 9, 2016: Sanofi
Jun 10, 2016: JDRF
Jan 21, 2016: RLS
Nov 13, 2012: Colby Pharmaceuticals
Apr 30, 2012: Tolero Pharmaceuticals
Feb, 2012: Torrey Pines Institute
Jan 19, 2011: TechnoVax
Sep 26, 2008: Rose Pharma
May 8, 2008: The Leukemia & Lymphoma Society
Anything missing from this timeline?
|
|
|
|
Post by mnkdfann on Jan 9, 2019 16:34:04 GMT -5
The list is nice, but it would be even nicer if it told us which 'deals' have seen any movement in recent years, or are even still in place.
|
|
|
|
Post by lakers on Jan 9, 2019 16:36:07 GMT -5
abstracts.aaps.org/Verify/aaps2013/postersubmissions/T3083.pdf Stability of Novel Pain Therapy Tetrapeptide TPI-23 in Technosphere® Inhalation Powder and Identification of Related-Compounds by Liquid Chromatography/Mass Spectrometry Y. Livson, E. Harris, K. Fabio, J. Guarneri MannKind Corporation Read more: mnkd.proboards.com/thread/4017/pain-management-plans#ixzz5c9HK6l00 |
|
|
|
Post by #NoMoreNeedles on Jan 9, 2019 16:50:37 GMT -5
Well, the company should showcase what's active on their pipeline page! Let's see whether Mike will follow through on his promise to publish a brand new corporate website.
|
|
